ABBV NYSE Week ended 18 Sep 2026

Weekly Investor Report

AbbVie Inc · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 263.96 USD
2.7% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 14.0% above the Trend Line and sits at 95.4% of its 52-week range. The latest completed week returned 2.7%, after a -0.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 42/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal; earnings are due in 39d.

Setup score 58 out of 100
Latest Close 263.96 USD 18 Sep 2026
1W Return 2.7% latest completed week
4W Return -0.4% short-term follow-through
12W Return 4.9% quarterly tape
Trend Breadth 71.2% 37 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 12-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 4 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.7% Latest completed week; four-week move -0.4%. Indicator stack 81/52 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 42/100 conviction; expected move 2.6%. News sentiment 57/100 91 relevant articles in the latest sentiment read. Event risk 39d Next report is scheduled for 30 Oct 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.0% above the Trend Line and sits at 95.4% of its 52-week range. The latest completed week returned 2.7%, after a -0.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug 14 Aug 21 Aug 28 Aug 4 Sep 11 Sep 18 Sep
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8912-week average 0.71

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.89Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.4% over four weeks, 4.9% over 12 weeks, and 21.5% over one year. The current trend has remained active for 12 consecutive weeks.

Performance by holding period

1W2.7%
4W-0.4%
12W4.9%
26W29.8%
52W21.5%
Active trend streak12 weeks
Active weeks in one year37
Trend breadth71.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.36Latest activity-pressure read.
Pressure change-57.4%Four-week change in activity pressure.
Leadership7.15Latest relative-leadership reading.
RS change-5.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 18 Sep 2026 Financial statements through 30 Jun 2026 Field coverage 94% Model confidence 94%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength35/100Blend of value, momentum, and quality. Underlying universe rank 66; rank 1 is best.
Value10/100Relative valuation strength. Underlying universe rank 91; rank 1 is best.
Quality80/100Profitability and accounting quality. Underlying universe rank 21; rank 1 is best.
Momentum70/100Medium-term price momentum. Underlying universe rank 31; rank 1 is best.
Growth32/100Revenue and earnings growth. Underlying universe rank 69; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
73.9x
Price divided by trailing earnings.
Price / sales
7.2x
Market value relative to trailing revenue.
EV / EBITDA
19.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
71.5%
Gross profit retained from each unit of revenue.
Operating margin
29.3%
Operating profit retained from revenue.
Free-cash-flow margin
28.2%
Free cash flow generated from revenue.
Return on invested capital
23.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
10.4%
Latest one-year revenue growth.
EPS growth
67.8%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-0.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.6%
Cash dividends relative to market value.
Buyback yield
0.3%
Net share repurchases relative to market value.
Shareholder yield
2.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

ABBV shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.47, expected move of 2.6%, and Sharemaestro trend signal active.

Conviction42/100
Expected move2.6%
Put/call volume0.47
Pressure38
Speculation41
Volatility27
Trend agreement56
Open options detail
Insider activity17 / 2

17 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 91 relevant articles.

24 positive · 63 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings39dNext report is scheduled for 30 Oct 2026; event risk rises as the date approaches.
Options expected move2.6%Nearest-chain priced movement where available.
52-week drawdown-1.3%Distance below the 52-week high.
13-week volatility5.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+17.0%Week of 26 Jun.
Worst week-5.0%Week of 10 Jul.
Latest week+2.7%Week of 18 Sep.

Shape of recent returns

Strong gains4
Modest gains12
Flat weeks0
Modest losses7
Sharp losses3
Recent vol5.4%13-week weekly-return volatility.
Base vol3.8%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew3.0% / -2.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape60/100

Trend, activity pressure, participation, and risk combine to a 60/100 tape read.

 Indicator analysis80/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 11/12.

Activity pressure 0.89; 4 reversal markers Factors48/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 31 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options59/100

ABBV shows bullish options pressure with a 42/100 conviction score, put-call volume ratio of 0.47, expected move of 2.6%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 2.6% Sentiment57/100

Weighted news tone is neutral across 91 relevant articles.

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery Insiders17 / 2

17 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings39d

Next report is scheduled for 30 Oct 2026; event risk rises as the date approaches.

 Research flow5 items

2 recent research articles and 3 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
18 Sep 2026263.96 USD2.7%231.45 USD188.94 USD0.367.1524.4MOn
11 Sep 2026257.12 USD0.3%230.08 USD188.13 USD0.534.3818.1MOn
4 Sep 2026256.46 USD0.4%229.16 USD187.37 USD0.643.3720.0MOn
28 Aug 2026255.48 USD-3.6%228.00 USD186.59 USD0.723.1518.9MOn
21 Aug 2026264.96 USD6.2%226.86 USD185.82 USD0.857.5525.6MOn
14 Aug 2026249.46 USD1.4%225.27 USD184.97 USD0.850.0221.0MOn
7 Aug 2026246.04 USD-2.0%224.05 USD184.24 USD0.96-1.1830.2MOn
31 Jul 2026250.94 USD-3.2%223.06 USD183.55 USD1.074.4031.7MOn
24 Jul 2026259.36 USD1.9%222.22 USD182.80 USD1.169.2622.9MOn
17 Jul 2026254.49 USD3.3%221.11 USD182.02 USD1.286.9429.2MOn
10 Jul 2026246.33 USD-5.0%220.07 USD181.22 USD1.092.1835.7MOn
3 Jul 2026259.23 USD3.0%219.18 USD180.43 USD0.949.1630.9MOn
26 Jun 2026251.57 USD17.0%217.95 USD179.55 USD0.758.5787.5MOff
19 Jun 2026214.97 USD-4.9%217.04 USD178.71 USD0.33-9.1326.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context